Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y., Jan. 27, 2021 /PRNewswire/ -- Columbia University researchers and Regeneron have independently confirmed findings; data included in bioRxiv paper and submitted for peer-reviewed publication Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that researchers in...

REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa

Eli Lilly

Eli Lilly is back with another round of promising data on its Covid-19 antibody therapies.

Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails

Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and position it for growth in 2021.

Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?

Shares of Regeneron Pharmaceuticals Inc. were up 1.8% in premarket trading on Tuesday after the company said its COVID-19 antibody cocktail can prevent people at high risk of a COVID-19 infection from contracting the virus. These are the initial results from an ongoing Phase 3 clinical trial for what Regeneron calls a "passive vaccine.

Regeneron says its COVID-19 antibody cocktail can prevent infections, based on late-stage study

TARRYTOWN, N.Y., Jan. 26, 2021 /PRNewswire/ -- Reduction in overall infections seen within first week, with 100% prevention of symptomatic infections Markedly decreased levels and duration of viral shedding in asymptomatic infections that still occurred in REGEN-COV group Confirmatory...

Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19

Aurinia Pharmaceuticals

AstraZeneca

Constellation Pharmaceuticals Inc

AstraZeneca (NASDAQ: AZN) shares are trading higher Monday after the company's CALQUENCE met its primary efficacy endpoint. The German Health Minister also said he expects the EU to approve the company's COVID-19 vaccine on Friday.

Why Aurinia Pharma, AstraZeneca And More Are Trading Higher Today

BMO Capital Markets analyst Matthew Luchini upgraded the stock to Outperform on Monday.

Regeneron Stock Jumps After Analyst Says Now Could Be a Good Time to Buy

REGN reached a $2.6 billion COVID-19 supply deal with the government. The recent deal could have a sizeable impact on REGN's revenue and EBITDA. The question remains, "How much is recurring?"

Regeneron Negotiates COVID-19 Supply To Beat Back Merck

TARRYTOWN, N.Y. and WASHINGTON, Jan. 21, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in the Regeneron Science Talent Search 2021, the nation's oldest and most prestigious science and math competition...

Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021

TARRYTOWN, N.Y., Jan. 19, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2020 financial and operating results on Friday, February 5, 2021, before the U.S. financial markets open. The Company will...

Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021

This high-growing, blue-chip biotech has just what it takes to make investors rich.

Could Regeneron Pharmaceuticals Be a Millionaire-Maker Stock?

Amazon

GameStop

Plug Power

Amazon, Plug Power, GameStop and Regeneron were our top stock trades for Thursday. Let's have a look at the charts after some big moves.

4 Top Stock Trades for Thursday: AMZN, PLUG, GME, REGN

Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail.

Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment

Jaguar Health

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the total number to over 1.5 million doses. Regeneron discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation.

Why Regeneron, Jaguar Health And Seneca Are Moving Today

Rapid expansion beyond the Eylea franchise is causing analysts to raise their ratings on the big biotech.

Is Regeneron Stock Heading to $590?

One analyst estimates that the deal could add $1.6 billion to the biotech's revenue. The deal gives the drug an effective price of $2,100 a dose.

Regeneron Inks Deal to Sell Covid-19 Treatment to U.S., Even as Usage Lags

Biotech company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the signing of a $2.625 billion supply agreement with the U.S. government for its COVID-19 antibody cocktail. What Happened: The U.S. Department of Health and Human Services and the Department of Defense have decided to buy an additional 1.25 million doses of Casirivimab and Imdevimab antibody cocktail.

Regeneron To Supply US With Another 1.25M COVID-19 Treatment Doses

Regeneron Pharmaceuticals Inc. said late Tuesday that the U.S. government has agreed to buy an additional 1.25 million doses of the company's COVID-19 antibody cocktail. That would bring the U.S. supply of the cocktail, consisting of casirivimab and imdevimab antibodies, to more than 1.5 million doses.

Regeneron says U.S. government to buy 1.25 million doses of its COVID-19 treatment

TARRYTOWN, N.Y., Jan. 12, 2021 /PRNewswire/ -- New agreement covers 1.25 million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. supply to over 1.5 million doses Doses are being supplied for use pursuant to the FDA Emergency Use...

Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

Biotech stocks gained after a Regeneron (REGN) upgrade. Trade the stock and industry heavyweight Incyte (INCY) with these tactical ideas.

Regeneron (REGN) Upgrade Lifts Range-Bound Biotech Stocks

In a note out Friday morning, Citi analyst Mohit Bansal says that weakness makes it a good time to buy.

A Case to Buy Regeneron Stock After Its Recent Tumble

Regeneron (REGN) reports positive initial data on its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen.

Regeneron (REGN) Releases Initial Data on Cocktail for COVID-19

The antibody infusions help infected patients who haven't yet generated antibodies of their own fight the virus.

Regeneron's Antibodies Appear to Help Hospitalized Patients—and Could Help 2021 Revenue

Regeneron Pharmaceuticals Inc. said initial data from its Phase 1/2/3 clinical trial of its antibody cocktail in hospitalized COVID-19 patients requiring low-flow oxygen passed a futility analysis, meaning there was sufficient efficacy to warrant continuing the trial. "The results passed the futility analysis (p

News for Regeneron Pharmaceuticals Stock (REGN)